Tech Millionaire Bryan Johnson Halts Use of Longevity Drug Rapamycin

author
1 minute, 57 seconds Read

Bryan Johnson, the 47-year-old tech entrepreneur famously dubbed “the man who wants to live forever,” has officially ceased using the controversial longevity drug rapamycin.

Johnson, who spends over $2 million annually on cutting-edge medical treatments to slow down aging, shared his decision on social media, citing concerns that the drug might be accelerating aging rather than reversing it.

Johnson has gained global attention for his ambitious efforts to combat the effects of aging, including a daily regimen of 54 supplements and a strict health protocol overseen by a team of medical experts.

His lifestyle is a cornerstone of his commitment to pioneering anti-aging research, but his recent revelation marks a turning point in his five-year trial with rapamycin, a drug celebrated for its ability to extend the lifespans of mice.

Despite its promising reputation in longevity research, rapamycin has not been approved by the U.S. Food and Drug Administration (FDA) for anti-aging purposes.

The drug works by inhibiting a protein called mTOR, which is associated with cell growth and aging. While it has shown significant potential in animal studies, its safety and efficacy in humans remain controversial.

Johnson explained that he and his medical team decided to discontinue rapamycin after observing a range of adverse side effects.

These included skin infections, elevated cholesterol levels, glucose metabolism issues, and increased heart rates.

Furthermore, Johnson referenced scientific studies suggesting that the drug could impair immune function, disrupt metabolic processes, and potentially raise the risk of certain cancers.

“While rapamycin has shown remarkable results in lab studies, the potential trade-offs in human applications are too significant to ignore,” Johnson said in his statement.

“Our goal is not just to live longer, but to live better, healthier lives. Rapamycin, for now, doesn’t align with that vision.”

The decision underscores the complexities of translating experimental anti-aging treatments into practical, safe applications for humans.

Johnson’s approach has always been data-driven, relying on biomarkers, rigorous testing, and the latest scientific advancements.

His move away from rapamycin highlights the need for further research into the long-term effects of such drugs on human health.

As Johnson continues his quest to slow the aging process, his journey serves as both an inspiration and a cautionary tale for those exploring the frontiers of longevity science.

His emphasis on balancing ambition with safety could shape the future of anti-aging medicine for years to come.


Similar Posts